# Ayala Pharmaceuticals Inc. (AYLA)

Source: https://www.quantisnow.com/company/AYLA
Generated: 2026-11-15T04:15:04.562Z

- Ticker: AYLA
- Exchange: NASDAQ
- Sector: Consumer Discretionary
- Industry: Specialty Chemicals
- IPO year: 2020
- Website: ayalapharma.com

## About

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

## Latest AYLA news and filings

- 2023-11-01 20:04 UTC [SEC Form 3] [SEC Form 3 filed by new insider Martell Bridget A](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-martell-bridget-a-5050363)
- 2023-11-01 20:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Orbach Pini](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-orbach-pini-5050297)
- 2023-10-31 21:48 UTC [SEC Form 3] [SEC Form 3 filed by new insider Golan Roy](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-golan-roy-5048035)
- 2023-03-31 10:38 UTC [SEC Form 10-K] [SEC Form 10-K filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-ayala-pharmaceuticals-inc-4276683)
- 2023-02-08 22:16 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-ayala-pharmaceuticals-inc-amendment-4025953)
- 2023-02-07 11:01 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-ayala-pharmaceuticals-inc-4012114)
- 2023-02-06 19:49 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-ayala-pharmaceuticals-inc-amendment-4009137)
- 2023-01-30 20:30 UTC [SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-ayala-pharmaceuticals-inc-3973324)
- 2023-01-25 21:53 UTC [SEC Form 8-K] [Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets](https://www.quantisnow.com/insight/ayala-pharmaceuticals-inc-filed-sec-form-8-k-completion-of-acquisition-3955140)
- 2023-01-24 15:21 UTC [SEC Form 4] [SEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company](https://www.quantisnow.com/insight/sec-form-4-amoon-growth-fund-limited-partnership-returned-2991473-3945583)
- 2023-01-24 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-ayala-pharmaceuticals-inc-3943117)
- 2023-01-24 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-ayala-pharmaceuticals-inc-3943108)
- 2023-01-24 02:00 UTC [SEC Form 4] [SEC Form 4: Maimon Yossi returned 69,872 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-maimon-yossi-returned-69872-shares-to-the-3942610)
- 2023-01-24 02:00 UTC [SEC Form 4] [SEC Form 4 filed by Spiegel Robert J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-spiegel-robert-j-3942608)
- 2023-01-24 02:00 UTC [SEC Form 4] [SEC Form 4: Sidransky David returned 250 shares to the company](https://www.quantisnow.com/insight/sec-form-4-sidransky-david-returned-250-shares-to-the-3942607)
- 2023-01-24 02:00 UTC [SEC Form 4] [SEC Form 4: Mamluk Roni returned 265,345 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-mamluk-roni-returned-265345-shares-to-the-3942605)
- 2023-01-24 02:00 UTC [SEC Form 4] [SEC Form 4 filed by Bisker-Leib Vered](https://www.quantisnow.com/insight/sec-form-4-filed-by-bisker-leib-vered-3942604)
- 2023-01-24 02:00 UTC [SEC Form 4] [SEC Form 4 filed by Goldberg Murray A](https://www.quantisnow.com/insight/sec-form-4-filed-by-goldberg-murray-a-3942603)
- 2023-01-24 02:00 UTC [SEC Form 4] [SEC Form 4: Gordon Gary B. returned 58,520 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-gordon-gary-b-returned-58520-shares-to-3942602)
- 2023-01-23 21:29 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-ayala-pharmaceuticals-inc-amendment-3941751)
- 2023-01-19 20:51 UTC [SEC Form POS AM filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-ayala-pharmaceuticals-inc-3930315)
- 2023-01-19 20:43 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ayala-pharmaceuticals-inc-3930288)
- 2023-01-19 20:42 UTC [SEC Form POS AM filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-ayala-pharmaceuticals-inc-3930282)
- 2023-01-19 20:32 UTC [SEC Form 25-NSE filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-ayala-pharmaceuticals-inc-3930244)
- 2023-01-19 14:37 UTC [Advaxis and Ayala Pharmaceuticals Complete Merger](https://www.quantisnow.com/insight/advaxis-and-ayala-pharmaceuticals-complete-merger-3928439)
- 2023-01-13 21:01 UTC [SEC Form 8-K] [Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/ayala-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-3911391)
- 2023-01-10 21:31 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-after-market-session-3896990)
- 2023-01-09 11:51 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-ayala-pharmaceuticals-inc-amendment-3886589)
- 2023-01-04 22:15 UTC [Market Insight] [Ayala Pharmaceuticals Says On Dec. 15, 2022, Purported Stockholder Filed Complaint In U.S. District Court For Southern District Of New York Against Co.; Says Nine Purported Stockholders Sent Letters Alleging Deficiencies In Co.'s Proxy Statement](https://www.quantisnow.com/insight/ayala-pharmaceuticals-says-on-dec-15-2022-purported-stockholder-filed-3872991)
- 2023-01-04 22:06 UTC [SEC Form 425] [SEC Form 425 filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-ayala-pharmaceuticals-inc-3872822)
- 2023-01-04 22:03 UTC [SEC Form 8-K] [Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/ayala-pharmaceuticals-inc-filed-sec-form-8-k-other-events-3872779)
- 2023-01-03 17:54 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Tuesday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-tuesday-3863718)
- 2022-12-28 16:23 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Wednesday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-wednesday-3849630)
- 2022-12-27 13:07 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-pre-market-session-3844860)
- 2022-12-15 16:19 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Thursday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-thursday-3811459)
- 2022-12-12 21:44 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Ayala Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-ayala-pharmaceuticals-inc-3796063)
- 2022-11-29 17:31 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-intraday-session-3743937)
- 2022-11-23 21:03 UTC [SEC Form 8-K] [Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/ayala-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-3727927)
- 2022-11-17 21:35 UTC [SEC Form 8-K] [Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/ayala-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-3705069)
- 2022-11-17 13:00 UTC [Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting](https://www.quantisnow.com/insight/ayala-pharmaceuticals-presents-poster-on-al102-in-desmoid-tumors-at-3700767)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AYLA
- Earnings history: https://www.quantisnow.com/earnings/AYLA
- Dividend history: https://www.quantisnow.com/dividends/AYLA
- Insider transactions: https://www.quantisnow.com/insiders/AYLA
- Options chain: https://www.quantisnow.com/options/AYLA
- SEC 8-K filings only: https://www.quantisnow.com/company/AYLA/8-k
- RSS and alerts for AYLA: https://www.quantisnow.com/docs/rss-feeds.md